Milcanipran (Norepinephrine Reuptake Inhibitor) for Autism

Aug 5 2013
America/New York
Location: 
Autism and Obsessive Compulsive Spectrum Program at Albert Einstein College of Medicine/Montefiore Medical Center; Bronx, NY

Description

Milnacipran is a drug currently approved by the FDA for Fibromyagia but not yet for Autism. We are investigating whether Milnacipran is helpful in improving attentional deficits, irritability, repetitive behaviors, and social skills in adults with Autism Spectrum Disorder. The study will also use an fMRI machine to look at pictures of the brain to see if there are changes that result from Milnacipran for patients with Autism.

The study will last a maximum of 12 weeks and will require patients to come to our site in the Bronx for a visit every two weeks. 
 

Eligibility

Patients must be 18 years or older with an Autism Spectrum Diagnosis. He/she must have a verbal IQ of 70 or above and cannot have a neurological, psychological, or medical disorder (not including OCD and ADHD). Patients cannot be suicidal or pregnant. 
 

Contact Information

Emma Racine
Study Supervisor
718-653-4859 x 223
eracine@montefiore.org

http://www.einstein.yu.edu/departments/psychiatry-behavioral-sciences/autism-program/autism-program.aspx?id=36040